Villere ST Denis J & Co. LLC Has $8.27 Million Position in Johnson & Johnson (JNJ)
Villere ST Denis J & Co. LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 6.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,574 shares of the company’s stock after acquiring an additional 3,724 shares during the quarter. Villere ST Denis J & Co. LLC’s holdings in Johnson & Johnson were worth $8,265,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Harding Loevner LP bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. Lenox Wealth Advisors Inc. boosted its stake in Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the period. Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $124,000. Finally, Shine Investment Advisory Services Inc. bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $177,000. 65.71% of the stock is owned by institutional investors.
Johnson & Johnson (NYSE:JNJ) opened at $147.36 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $395,885.59, a P/E ratio of 20.64, a PEG ratio of 2.76 and a beta of 0.80. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $148.32.
Several research analysts have weighed in on JNJ shares. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.40 price target for the company in a research note on Monday, January 1st. Royal Bank of Canada upped their price target on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 18th. Citigroup started coverage on Johnson & Johnson in a research note on Monday, September 25th. They issued a “neutral” rating and a $140.00 price target for the company. Finally, Jefferies Group upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the stock from $145.00 to $157.00 in a research note on Wednesday, October 11th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $145.94.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.